Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Inovio Pharmaceuticals Inc (NASDAQ:INO)

6.01
Delayed Data
As of Jul 21
 0.00 / 0.00%
Today’s Change
5.83
Today|||52-Week Range
11.00
-13.40%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$466.6M

Company Description

Inovio Pharmaceuticals, Inc. is a bio pharmaceutical company. It develops active DNA immunotherapies for cancer and infectious diseases. The company's portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. Its pipeline consists vgx-3100, ino-3122, ino-3106, pennvax-b and pennvax-g. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Contact Information

Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Plymouth Meeting Pennsylvania 19462-1111
P:(267) 440-4200
Investor Relations:
(858) 410-3101

Employees

Shareholders

Individual stakeholders7.24%
Mutual fund holders15.34%
Other institutional11.99%

Top Executives

J. Joseph KimPresident, Chief Executive Officer & Director
Niranjan Y. SardesaiChief Operating Officer
Peter D. KiesChief Financial Officer
Jessica C. LeeVice President-Clinical Operations & Compliance
Mark L. BagarazziChief Medical Officer